AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02963584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision aid
Description: The related information about CTO and PCI procedures will be told to the patients thoroughly.
Study NCT04307472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Nudge
Description: Active choice intervention in the electronic health record and peer comparison messaging on performance
Study NCT01129206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
Study NCT01129206 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study NCT01129206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT03198403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
Study NCT02695277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure Bipolar System
Study NCT02695277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endocardial Ablation with Catheter
Study NCT02695277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriClip® PRO LAA Exclusion System
Study NCT02695277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial Ablation with Catheter
Study NCT02695277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Endocardial ablation(s)
Study NCT04331522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral provocation test
Description: Titrated provocation with allergen
Study NCT00238316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg PO daily for 1 year
Study NCT00238316 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mg PO daily for one 1 year
Study NCT02715960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin Capsules
Description: During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
Study NCT04002154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papilocare vaginal gel
Description: Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
Study NCT03546725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking
Description: Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
Study NCT02261168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized living protocol
Description: Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
Study NCT02254668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol with Everolimus (Certican®)
Description: Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
Study NCT02254668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol with Mycophenolate mofetil (CellCept®)
Description: Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
Study NCT04118439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imaginery and Action Observation
Description: A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
Study NCT04600141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
Study NCT01104259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given PO
Study NCT01104259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01104259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT01104259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01104259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03671824 — intervention group
Intervention type: OTHER
Intervention: Measurements
Description: Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
Study NCT01374815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Online Advocate
Description: The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
Study NCT01374815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Online Advocate
Description: The Online Advocate is a Web-based screening and referral tool for health-related social problems
Study NCT01345877 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: first degree cutaneous burn injury
Description: application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
Study NCT05528003 — intervention group
Intervention type: PROCEDURE
Intervention: Commercialized single-access port devices
Description: Two kinds of commercialized single-access port devices were used.
Study NCT01093924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PILI 'Ohana 18-month weight loss maintenance
Description: All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
Study NCT05127096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FirstSight blood test
Description: FirstSight blood test for colorectal cancer screening
Study NCT03950245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
Study NCT03950245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
Study NCT03950245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
Study NCT03950245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GLP-1 and GIP antagonism
Description: Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
Study NCT03338751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cognitive testing with HAD (PockeTalker) First
Description: tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
Study NCT03338751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing without HAD First
Description: tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
Study NCT04600141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin - Therapeutic dosage
Description: Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
Study NCT00400322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir (Valcyte)
Study NCT00400322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03757494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Stim
Description: Use of Alpha Stim Device
Study NCT04600141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin - Therapeutic dosage
Description: Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
Study NCT04600141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin - Prophylactic dosage
Description: Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
Study NCT04600141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin - Prophylactic dosage
Description: Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
Study NCT02860403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
Study NCT02133079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous gp96 vaccination
Description: vaccination of autologous gp96 derived from tumor tissue + basal treatment
Study NCT03073512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound examination
Description: Participants will undergo ultrasound examination at 32 weeks gestation
Study NCT01716000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal gel imaging
Description: Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
Study NCT01716000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer aided self interview
Description: Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
Study NCT04429763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord derived mesenchymal stem cells
Description: One dosis of 1\*10\^6 cells/Kg
Study NCT04429763 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01979185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT01979185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT01979185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Study NCT00526799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid
Study NCT00526799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 3.5mg/m2 weekly, 3 weeks on and one week off.
Study NCT04002128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.
Description: Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
Study NCT04002128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.
Description: Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
Study NCT01957384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product 1
Description: Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
Study NCT01957384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test product 2
Description: Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
Study NCT01957384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)
Description: Standard Care was the subject usual ostomy appliance and had to be one of the following:~* Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~* Dansac: Nova 1 \& Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~* Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~* ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~* B. Braun: Flexima Active \& Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate
Study NCT05586750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: 40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
Study NCT01682954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 16-week nutrition, physical activity and behavioral intervention
Study NCT00319501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular autoinjector; administered at onset of an episode
Study NCT00319501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanquix Auto-Injector (Diazepam Injection)
Description: Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
Study NCT00740571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: strategy in which the patient starts with amitriptyline, during 8 weeks
Study NCT00740571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Strategy in which patient starts with pregabalin
Study NCT03360604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Diet
Description: This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
Study NCT03360604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Glycaemic Diet
Description: This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
Study NCT04226872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Tools for Care - In Care
Description: Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
Study NCT02264561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food
Description: Active group
Study NCT02264561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Active group
Study NCT02264561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food
Description: Control group
Study NCT02264561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Control group
Study NCT02694965 — intervention group
Intervention type: OTHER
Intervention: observational
Study NCT02426944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: Medical arm, patients will be treated by NOAC.
Study NCT02426944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: The patients will be treated by interventional closure of the left atrial appendage.
Study NCT04046692 — intervention group
Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the children
Description: Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
Study NCT04046692 — intervention group
Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the hospital teachers
Description: operators interview hospital teachers and make them complete a questionnaire (CEESQ)
Study NCT04046692 — intervention group
Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the non hospital teachers
Description: operators interview the teachers and make them complete a questionnaire (CEESQ)
Study NCT04046692 — intervention group
Intervention type: OTHER
Intervention: Hospital School Experience, point of view of parents
Description: Operators interview parents
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib with Capecitabine
Description: If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)
Description: B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti PD-1 with nab-paclitaxel
Description: If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
Study NCT01588015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus-CMV fusion peptide vaccine
Description: Given SC
Study NCT01588015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01588015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00831792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK1258
Description: 4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
Study NCT03771027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The low FODMAP diet.
Description: The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
Study NCT03771027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The diet based on NICE guidelines.
Description: The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
Study NCT03046290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision
Study NCT03046290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT03046290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT03032796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body-Brain Trainer
Description: A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.